Pharmaceutical News

NEW YORK--(BUSINESS WIRE)--Blue Matter today announced the launch of an expanded policy capability to support biopharma clients, led by Milena Sullivan, a Partner who joined the firm in December 2025. Milena Sullivan brings more than 20 years of experience in healthcare policy, advocacy, and market access, advising life science companies, trade associations, and provider organizations on policy issues shaping their business. Prior to joining Blue Matter, she spent almost a decade with Avalere H...

CHICAGO--(BUSINESS WIRE)--GE HealthCare will showcase its latest enterprise imaging solutions at the Society for Imaging Informatics in Medicine (SIIM) 2026 Annual Meeting in Pittsburgh, PA. Medical imaging departments today are under immense pressure from all sides including rising imaging volumes and increasing case complexity, while staffing shortages continue to grow. According to the American College of Radiology (ACR), radiologist workforce shortages have been identified as the biggest th...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that ARK Invest has joined the company's Series D financing with a $20 million investment, bringing the total Series D to $277 million. ARK joins a high-caliber group of Cellares investors, including BlackRock, Eclipse, T. Rowe Price Investment Management, Inc., Baillie Gifford, Duquesne Family Office, Intuitive Ventures, EDBI, Gates Frontier, DC Global...

SOLON, Ohio--(BUSINESS WIRE)--Multi Radiance Medical (MRM), a global leader in Super Pulsed Laser therapy technology and photobiomodulation research, announces that the U.S. Food and Drug Administration (FDA) has granted NHN 510(k) clearance for the adjunctive use of the MR5 ACTIV PRO Super Pulsed Laser for the temporary relief of pain associated with lateral epicondylitis. Lateral epicondylitis (LE) is one of the most common causes of elbow pain, affecting an estimated 10.5 million adults annu...

DALLAS--(BUSINESS WIRE)--Pharmaceutical Strategies Group (“PSG”), an EPIC company, today released its 2026 Trends in Drug Benefit Design Report, sponsored by Transcarent, highlighting how payers are adjusting pharmacy benefit strategies amid evolving GLP-1 utilization, heightened focus on alternative pharmacy benefit management (PBM) models, and rising pressure around drug pricing and member cost sharing. PSG’s annual research has tracked trends shaping drug benefit design and management for mo...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that Dr. Jost Reinhard has been appointed President of the Radiology business within Bayer’s Pharmaceuticals Division, effective August 1, 2026. In his new capacity, he will report to Stefan Oelrich, Member of the Board of Management of Bayer AG and President of the company’s Pharmaceuticals Division. Reinhard follows Nelson Ambrogio, who became President of Bayer U.S. Pharmaceuticals in May 2026. “With a compelling performance in recent ye...

BERKELEY, Calif.--(BUSINESS WIRE)--AI can predict a protein’s 3D shape and help design molecules that fit it. Tools like OpenFold make drug discovery faster, cheaper, and more precise....

NEW YORK--(BUSINESS WIRE)--Wisp, the largest pure play women’s telehealth company in the U.S., today announced a collaboration with the Mount Sinai Health System, one of the largest academic medical systems in the New York metro area, to expand access to PrEP and HIV prevention to sexually active men, women and individuals across New York State. This collaboration is the first fully remote HIV prevention program launched by a New York City medical system — enhancing privacy, convenience, and ac...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company’s clinical program for fasedienol nasal spray for the acute treatment of social anxiety disorder has achieved the minimum patient exposures as recommended under ICH E1, the international regulatory...

MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company advancing molecularly targeted intraoperative imaging, today announced the appointment of Adam Gridley as President and Chief Executive Officer. Mr. Gridley succeeds John Santini, Ph.D., who will transition to the role of Chief Technology Officer, continuing to lead the company’s scientific innovation and long-term technology strategy. Mr. Gridley brings more than 30 years of commercial and late-stage clini...